AIN457 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Plaque-type Psoriasis

Conditions

Plaque-type Psoriasis

Trial Timeline

May 11, 2010 → Oct 18, 2016

NCT ID

NCT01132612

About AIN457 + Placebo

AIN457 + Placebo is a phase 2 stage product being developed by Novartis for Plaque-type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01132612. Target conditions include Plaque-type Psoriasis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01090310	Phase 3	Terminated	Aug 1, 2010	Jul 1, 2011	Non-infectious Uveitis
NCT01132612	Phase 2	Completed	May 11, 2010	Oct 18, 2016	Plaque-type Psoriasis
NCT01071252	Phase 2	Completed	Mar 1, 2010	Feb 1, 2011	Chronic Plaque-type Psoriasis
NCT01051817	Phase 2	Completed	Dec 1, 2009	Apr 1, 2012	Relapsing-remitting Multiple Sclerosis
NCT00809614	Phase 2	Completed	Mar 1, 2009	Dec 1, 2010	Psoriatic Arthritis
NCT00809159	Phase 2	Completed	Mar 1, 2009	May 1, 2011	Ankylosing Spondylitis
NCT00805480	Phase 2	Completed	Dec 1, 2008	Sep 1, 2010	Chronic Plaque Psoriasis
NCT00770965	Phase 2	Completed	Sep 10, 2008	Sep 17, 2009	Chronic Plaque Psoriasis
NCT00584740	Phase 2	Terminated	Aug 1, 2008	Aug 1, 2010	Crohn's Disease
NCT00669916	Phase 1/2	Completed	Feb 1, 2007	Nov 1, 2007	Plaque Psoriasis
NCT00669942	Phase 1/2	Completed	Dec 1, 2005	Nov 1, 2008	Rheumatoid Arthritis

Competing Products

18 competing products in Plaque-type Psoriasis

See all competitors

Product	Company	Stage	Hype Score
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mg	Sun Pharmaceutical	Phase 3	77
AIN457 150 mg + AIN457 300 mg + Placebo	Novartis	Phase 3	77
AIN457 + AIN457A + AIN457A + Placebo	Novartis	Phase 2	52
secukinumab + placebo	Novartis	Phase 2	52
secukinumab 150 mg	Novartis	Phase 3	77
Experimental : Secukinumab low dose + Experimental: Secukinumab high dose + Placebo Comparator: Secukinumab Placebo + Active Comparator: Etanercept	Novartis	Phase 3	77
Placebo + Secukinumab 150mg + Secukinumab 300mg	Novartis	Phase 3	77
Secukinumab	Novartis	Phase 3	77
AIN457 + Placebo	Novartis	Phase 2	52
Secukinumab (AIN457) + Placebo	Novartis	Phase 3	77
secukinumab 150 mg + placebo to secukinumab 150 mg	Novartis	Phase 3	77
secukinumab low dose + secukinumab high dose	Novartis	Phase 3	77
AIN457 150mg + AIN457 300mg	Novartis	Phase 3	77
secukinumab 150mg + secukinumab 10mg/kg i.v. regimen	Novartis	Phase 3	77
CJM112 + Secukinumab	Novartis	Phase 1	33
secukinumab 150 mg + secukinumab 300 mg + placebo	Novartis	Phase 3	77
AN2728 Ointment + AN2728 Vehicle	Pfizer	Phase 1	32
Olux-E Foam + Clobex lotion	GSK plc	Approved	84

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved